Categories: Entertainment

Cureus Updates Terms & Conditions to Prohibit AI Use

SAN FRANCISCO, Sept. 4, 2025 /PRNewswire/ — In an era dominated by artificial intelligence, the Cureus Journal of Medical Science is taking a bold stand against the unchecked use of human-authored research by large language models (LLMs). AI companies harvest open-access content to train algorithms, they justify this practice through broad interpretations of Creative Commons licenses. Cureus says: Your ideas belong to you and no machine gets to use them without your permission.

- Advertisement -

Cureus has updated its Terms & Conditions to explicitly prohibit the use of site content by artificial intelligence systems, including:

- Advertisement -
  • Training AI or machine learning models
  • Data mining or scraping
  • Creating derivative works based on Cureus articles

“In connection with your Use of the Site Content, you must…not use the Site Content in combination with artificial intelligence…to train an algorithm, machine learning tool, or other artificial intelligence technology.”

- Advertisement -

This isn’t just a legal change — it’s a declaration of values. Cureus believes authorship is a human right, and we’re committed to preserving the originality and intellectual integrity of every article we publish.

- Advertisement -

“We’re not anti-technology. We’re pro-human. We’re not anti-progress. We’re pro-author. In an age where machines can replicate text, but not insight, Cureus remains committed to amplifying authentic scientific voices. Because real knowledge isn’t just generated– it’s discovered, tested, and told by humans.”

- Advertisement -

– Professor John Adler, MD.
(co-founder, co-editor-in-chief)

- Advertisement -

Founded to democratize medical publishing, Cureus eliminates traditional barriers like APCs and paywalls. As part of Springer Nature, Cureus continues to lead innovation in open-access publishing.

- Advertisement -

Fast facts about Cureus:

- Advertisement -
  • Over 25,000 articles published in 2024
  • 6.3 million monthly article views
  • Indexed in PubMed Central, Google Scholar, Dimensions, and more
  • No APCs; sliding-scale editing fees
  • 52% acceptance rate

Media Contact:
Cureus Editorial Office
Email: info@cureus.com
Website: www.cureus.com

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/cureus-updates-terms–conditions-to-prohibit-ai-use-302546487.html

- Advertisement -
PRNW Agency

Recent Posts

NeuroDyne Drops: Sharp Mind, Enhanced Memory, and Lasting Focus As Nature Intended, Ingredients

NEURODYNE DROPS INTRODUCED AS A COGNITIVE WELLNESS SUPPLEMENT SUPPORTING HEALTHY MEMORY, FOCUS, AND MENTAL CLARITY…

2 hours ago

Optivell Officially Announced as a Vision Support Formula for Preventive Eye Wellness

New York City, NY, Jan. 17, 2026 (GLOBE NEWSWIRE) -- OPTIVELL INTRODUCED AS A NEW…

2 hours ago

Sugar Clean Drops: Top Blood Sugar Support Supplement for Metabolic Wellness and Energy Support

SUGAR CLEAN DROPS ANNOUNCED AS A NEW SUPPLEMENT SUPPORTING HEALTHY BLOOD SUGAR AND METABOLIC WELLNESS…

2 hours ago

DBV Technologies Announces 166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

Châtillon, France, January 16, 2026 DBV Technologies Announces €166.7 Million in Gross Proceeds Following the…

13 hours ago

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026 16:15 ET  | Source: Zenas BioPharma WALTHAM, Mass., Jan. 16, 2026 (GLOBE…

13 hours ago